Anastrozole


Concise Prescribing Info
Indications/Uses
Listed in dosage.
Dosage/Direction for Use
Adult: PO Adjuvant therapy for postmenopausal women with hormone receptor-positive early breast cancer; Breast cancer in postmenopausal women As monotherapy in hormone receptor-positive advanced cases or in patients with disease progression following tamoxifen therapy: 1 mg once daily. Treatment may be continued up to 5 years for adjuvant therapy or until tumour progression for advanced breast cancer.
Administration
May be taken with or without food.
Contraindications
As monotherapy in pre-menopausal women with breast cancer. Severe renal impairment (CrCl <20 mL/min). Pregnancy and lactation.
Special Precautions
Patient with hyperlipidaemia; pre-existing osteopenia, ischaemic cardiac disease. Moderate to severe hepatic or mild to moderate renal impairment. Patient Counselling This drug may cause asthenia and somnolence, if affected, do not drive or operate machinery. Monitoring Parameters Perform pregnancy test prior to initiation of treatment in women with child-bearing potential. Monitor BMD, total cholesterol, LDL, CNS changes, hypotension, thrombophlebitis, bone pain or fracture at regular intervals during therapy.
Adverse Reactions
Significant: Decreased BMD (e.g. osteoporosis), hypercholesterolaemia, hypersensitivity reactions (e.g. anaphylaxis, angioedema, urticaria), ischaemic heart disease. Blood and lymphatic system disorders: Lymphoedema. Cardiac disorders: Angina pectoris, dyspnoea, chest pain. Eye disorders: Cataract. Gastrointestinal disorders: Gastrointestinal distress, anorexia, nausea, vomiting, constipation, diarrhoea, abdominal pain, dyspepsia, gastrointestinal disease, xerostomia. General disorders and administration site conditions: Fatigue, pain, weakness. Injury, poisoning and procedural complications: Bone fracture, accidental injury. Investigations: Weight gain. Metabolism and nutrition disorders: Oedema. Musculoskeletal and connective tissue disorders: Arthritis, myalgia, arthralgia, back pain, ostealgia. Nervous system disorders: Headache, dizziness, paraesthesia, carpal tunnel syndrome. Psychiatric disorders: Mood disorder, depression, insomnia, anxiety. Renal and urinary disorders: UTI. Reproductive system and breast disorders: Pelvic pain, mastalgia, vulvovaginitis, vaginal dryness or bleeding. Respiratory, thoracic and mediastinal disorders: Pharyngitis, cough, flu-like symptoms, sinusitis. Skin and subcutaneous tissue disorders: Rash. Vascular disorders: Vasodilation, hypertension, hot flushes.
Drug Interactions
Diminished therapeutic effect with oestrogen derivatives. Decreased serum concentration with tamoxifen.
ATC Classification
L02BG03 - anastrozole ; Belongs to the class of enzyme inhibitors. Used in endocrine therapy.
Disclaimer: This information is independently developed by CIMS based on anastrozole from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in